Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem By: TalkMarkets November 25, 2023 at 13:40 PM EST Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront payment, plus milestones and royalties. Read More >> Related Stocks: Astrazeneca Plc ADR Beigene Ltd ADR Connect Biopharma Holdings Ltd ADR Wuxi Biologics Cayman Inc ADR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem By: TalkMarkets November 25, 2023 at 13:40 PM EST Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront payment, plus milestones and royalties. Read More >> Related Stocks: Astrazeneca Plc ADR Beigene Ltd ADR Connect Biopharma Holdings Ltd ADR Wuxi Biologics Cayman Inc ADR